Gliclazide BP 80 mg
Glucoact: Each tablet contains Gliclazide BP 80 mg.
Glucoact is indicated for the treatment of non insulin diabetes mellitus (NIDDM) of patients who require oral antidiabetic treatment. Glucoact (Gliclazide) is a second generation oral hypoglycemic sulfonylurea which stimulates the release of insulin from pancreatic β-cells by facilitating Ca+2 transport across the β-cell membranes and decrease hepatic glucose output.
The usual initial dose is 40 to 80 mg daily, gradually increased, if necessary up to 320 mg daily until adequate control is achieved. A single dose should not exceed 160 mg. When higher doses are required it should be taken twice daily, according to the main meals of the day.
Plasma clearance of Gliclazide is not altered in the elderly and steady state plasma levels are similar to those in adults under 65 years. Clinical experience in the elderly shows that it is effective and well tolerated.
Gliclazide as with other sulfonylureas is not indicated for the treatment of juvenile onset diabetes mellitus.